(UPI) – A combination of the drugs rituximab and ibrutinib was found in a clinical trial to extend patient survival from chronic lymphocytic leukemia.
A two-drug combo helps patients with a common form of leukemia survive longer than the current standard of care, a new clinical trial finds.
The phase 3 trial of more than 500 U.S. patients with chronic lymphocytic leukemia, or CLL, found that a combination of rituximab and ibrutinib extended patient survival.
Advertisement - story continues below
Specifically, 89.4 percent of the patients who received the experimental drug combination did not have any progression of their leukemia about three years after treatment, compared with 72.9 percent of those who received the traditional chemotherapy combination.
As to overall survival, regardless of whether the disease had progressed or not, the trial found that three years after treatment, 98.8 percent of patients who received the two-drug combination were alive, compared with 91.5 percent of those who received the traditional treatment.